Serum anandamide and lipids associated with linoleic acid can distinguish interstitial cystitis/bladder pain syndrome from overactive bladder: An exploratory study.
anandamide
bladder pain syndrome
endocannabinoid
interstitial cystitis
linoleic acid
Journal
Lower urinary tract symptoms
ISSN: 1757-5672
Titre abrégé: Low Urin Tract Symptoms
Pays: Australia
ID NLM: 101506777
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
revised:
23
08
2023
received:
09
06
2023
accepted:
29
08
2023
medline:
6
11
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
ppublish
Résumé
Diagnosing interstitial cystitis/bladder pain syndrome presents a major challenge because it relies on subjective symptoms and empirical cystoscopic findings. A practical biomarker should discriminate diseases that cause increased urinary frequency, particularly overactive bladder. Therefore, we aimed to identify blood biomarkers that can discriminate between interstitial cystitis/bladder pain syndrome and overactive bladder. We enrolled patients with Hunner-type interstitial cystitis (n = 20), bladder pain syndrome (n = 20), and overactive bladder (n = 20) and without lower urinary tract symptoms (controls, n = 15) at Ueda Clinic and Nara Medical University Hospital from February 2020 to August 2021. The degree of interstitial cystitis/bladder pain syndrome symptoms was evaluated using the interstitial cystitis symptom and problem indices. Metabolomics analysis was performed on 323 serum metabolites using liquid chromatography time-of-flight mass spectrometry. In the Hunner-type interstitial cystitis or bladder pain syndrome group, we observed smaller relative areas, including anandamide, acylcarnitine (18:2), linoleoyl ethanolamide, and arachidonic acid, compared to those in the overactive bladder or control group. Notably, the differences in the relative areas of anandamide were statistically significant (median: 3.950e-005 and 4.150e-005 vs. 8.300e-005 and 9.800e-005), with an area under the curve of 0.9321, demonstrating its ability to discriminate interstitial cystitis/bladder pain syndrome. Serum anandamide may be a feasible diagnostic biomarker for interstitial cystitis/bladder pain syndrome. Reduced serum anandamide levels may be associated with pain and inflammation initiation, reflecting the pathology of interstitial cystitis/bladder pain syndrome. Furthermore, our findings suggest that abnormal linoleic acid metabolism may be involved in the pathogenesis of interstitial cystitis/bladder pain syndrome.
Substances chimiques
Linoleic Acid
9KJL21T0QJ
anandamide
UR5G69TJKH
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
238-246Subventions
Organisme : Grant-in-Aid for Scientific Research (C)
ID : 20K09566
Informations de copyright
© 2023 John Wiley & Sons Australia, Ltd.
Références
Homma Y, Akiyama Y, Tomoe H, et al. Clinical guidelines for interstitial cystitis/bladder pain syndrome. Int J Urol. 2020;27:578-589.
Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2022;208:34-42.
Yamada Y, Nomiya A, Niimi A, et al. A survey on clinical practice of interstitial cystitis in Japan. Transl Androl Urol. 2015;4:486-490.
Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int Urogynecol J. 2018;29:961-966.
Tonyali S, Ates D, Akbiyik F, Kankaya D, Baydar D, Ergen A. Urine nerve growth factor (NGF) level, bladder nerve staining and symptom/problem scores in patients with interstitial cystitis. Adv Clin Exp Med. 2018;27:159-163.
Magalhaes TF, Baracat EC, Doumouchtsis SK, Haddad JM. Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. Int Urogynecol J. 2019;30:1785-1794.
Chancellor MB, Lamb LE, Ward EP, et al. Comparing concentration of urinary inflammatory cytokines in interstitial cystitis, overactive bladder, urinary tract infection, and bladder cancer. Urol Sci. 2022;33:199-204.
Jiang YH, Jhang JF, Hsu YH, Kuo HC. Usefulness of urinary biomarkers for assessing bladder condition and histopathology in patients with interstitial cystitis/bladder pain syndrome. Int J Mol Sci. 2022;23:12044.
Torimoto K, Ueda T, Kasahara M, et al. Identification of diagnostic serum biomarkers for Hunner-type interstitial cystitis. Low Urin Tract Symptoms. 2022;14:334-340.
O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49:58-63.
Ohashi Y, Hirayama A, Ishikawa T, et al. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol Biosyst. 2008;4:135-147.
Ooga T, Sato H, Nagashima A, et al. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol Biosyst. 2011;7:1217-1223.
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics. 2010;6:78-95.
Lee LC, Liong CY, Jemain AA. Partial least squares-discriminant analysis (PLS-DA) for classification of high-dimensional (HD) data: a review of contemporary practice strategies and knowledge gaps. Analyst. 2018;143:3526-3539.
Lu HC, Mackie K. Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021;6:607-615.
Galiègue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995;232:54-61.
Tyagi P, Tyagi V, Yoshimura N, Chancellor M. Functional role of cannabinoid receptors in urinary bladder. Indian J Urol. 2010;26:26-35.
Ulugöl A. The endocannabinoid system as a potential therapeutic target for pain modulation. Balkan Med J. 2014;31:115-120.
Gratzke C, Streng T, Stief CG, et al. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol. 2010;57:1093-1100.
Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16:9-29.
Saitoh C, Kitada C, Uchida W, Chancellor MB, de Groat WC, Yoshimura N. The differential contractile responses to capsaicin and anandamide in muscle strips isolated from the rat urinary bladder. Eur J Pharmacol. 2007;570:182-187.
Gratzke C, Streng T, Park A, et al. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol. 2009;181:1939-1948.
Honda M, Yoshimura N, Kawamoto B, et al. Anandamide transporter-mediated regulation of the micturition reflex in urethane-anesthetized rats. Int Urol Nephrol. 2016;48:1407-1412.
Strittmatter F, Gandaglia G, Benigni F, et al. Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur Urol. 2012;61:98-106.
Walczak JS, Cervero F. Local activation of cannabinoid CB1 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents. Mol Pain. 2011;7:31.
Aizawa N, Hedlund P, Füllhase C, Ito H, Homma Y, Igawa J. Inhibition of peripheral FAAH depresses activities of bladder mechanosensitive nerve fibers of the rat. J Urol. 2014;192:956-963.
Christie S, Zagorodnyuk V. CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the Guinea pig bladder. Am J Physiol Renal Physiol. 2021;320:F859-F865.
De Groat WC, Griffiths D, Yoshimura N. Neural control of the lower urinary tract. Compr Physiol. 2015;5:327-396.
Mukerji G, Yiangou Y, Agarwal SK, Anand P. Increased cannabinoid receptor 1-immunoreactive nerve fibers in overactive and painful bladder disorders and their correlation with symptoms. Urology. 2010;75:1514.e15-1514.e20.
Bakali E, Mcdonald J, Elliot RA, Lambert DG, Tincello DG. Cannabinoid receptor expression in the bladder is altered in detrusor overactivity. Int Urogynecol J. 2016;27:129-139.
Füllhase C, Schreiber A, Giese A, et al. Spinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats. NeurourolUrodyn. 2016;35:464-470.
Kim SD, Cho KJ, Kim JC. Expression of cannabinoid 1 and, 2 receptors and the effects of cannabinoid 1 and, 2 receptor agonists on detrusor overactivity associated with bladder outlet obstruction in rats. BMC Urol. 2017;17:121.
Hsu LN, Hu JC, Chen PY, Lee WC, Chuang YC. Metabolic syndrome and overactive bladder syndrome may share common pathophysiologies. Biomedicine. 2022;10:1957.
Lee WC, Yu HR, Tain YL, Wu KLH, Chuang YC, Chan JYH. Vinpocetine ameliorates metabolic-syndrome-associated bladder overactivity in fructose-fed rats by restoring succinate-modulated cAMP levels and exerting anti-inflammatory effects in the bladder detrusor muscle. Biomedicine. 2022;10:2716.
Chen IH, Cheng JT, Tong YC. Metabolic syndrome induced bladder cannabinoid receptor changes in the fructose-fed rats. Low Urin Tract Symptoms. 2018;10:198-203.
Christie S, Brookes S, Zagorodnyuk V. Endocannabinoids in bladder sensory mechanisms in health and diseases. Front Pharmacol. 2021;12:708989.
Tambaro S, Casu MA, Mastinu A, Lazzari P. Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Eur J Pharmacol. 2014;15:67-74.
Berger G, Arora N, Burkovskiy I, et al. Experimental cannabinoid 2 receptor activation by phyto-derived and synthetic cannabinoid ligands in LPS-induced interstitial cystitis in mice. Molecules. 2019;24:4239.
Merriam FV, Wang Z, Guerios SD, Bjorling DE. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett. 2008;445:130-134.
Wang Z, Wang P, Bjorling DE. Treatment with a cannabinoid receptor 2 agonist decreases severity of established cystitis. J Urol. 2014;191:1153-1158.
Liu Q, Wu Z, Liu Y, et al. Cannabinoid receptor 2 activation decreases severity of cyclophosphamide-induced cystitis via regulating autophagy. NeurourolUrodyn. 2020;39:158-169.
Bjorling DE, Wang Z. Potential of endocannabinoids to control bladder pain. Front Syst Neurosci. 2018;12:17.
Akiyama Y, Homma Y, Maeda D. Pathology and terminology of interstitial cystitis/bladder pain syndrome: a review. Histol Histopathol. 2019;34:25-32.
Whelan J, Fritsche K. Linoleic acid. Adv Nutr. 2013;4:311-312.
Nomura DK, Morrison BE, Blankman JL, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011;334:809-813.
Sultana S, Berger G, Lehmann C. Components of the endogenous cannabinoid system as potential biomarkers for interstitial cystitis/bladder pain syndrome. Diagnostics (Basel). 2021;12:19.
Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 1994;372:686-691.
Kujala MM, Tammela TL, Pöyhönen A, et al. Prevalence of autoimmune disorders among bladder pain syndrome patients' relatives. Scand J Urol. 2021;55:72-77.
Charrua A, Matos R, Oliveira R, Marczylo T, Nagy I, Cruz F. Fatty acid amide hydrolase inhibition normalises bladder function and reduces pain through normalising the anandamide/palmitoylethanolamine ratio in the inflamed bladder of rats. Naunyn Schmiedebergs Arch Pharmacol. 2020;393:263-272.
Houbiers JGA, van Till JWO, Kaper M, et al. An adaptive randomized clinical trial in interstitial cystitis/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner's lesions. World J Urol. 2021;39:2065-2071.
Takizawa M, Hatta T, Iitsuka H, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of ASP3652, a reversible fatty acid amide hydrolase inhibitor, in healthy, nonelderly, Japanese men and elderly, Japanese men and women: a randomized, double-blind, placebo-controlled, single and multiple oral dose, phase I study. Clin Ther. 2020;42:906-923.
Ness TJ, Lloyd LK, Fillingim RB. An endogenous pain control system is altered in subjects with interstitial cystitis. J Urol. 2014;191:364-370.